By contrast, COBI-boosted EVG exposure is increased when given with food, with AUCtau and C max increased by 22–36% with light meals and by 56–91% with high-calorie, high-fat meals. Although it is recommended that Stribild is administered with food [23], the fasted EVG C24h (250 ng/mL) was well over the protein-adjusted IC95 for wild-type HIV (44.5 ng/mL) [23], suggesting that Stribild should provide adequate EVG exposure in the vast majority of fasted patients. The pharmacokinetic parameters of COBI and EVG are not affected by co-administration of this website omeprazole, a proton pump inhibitor, or famotidine, an H2-receptor antagonist [24]. Neither

COBI nor EVG requires dose modification in patients with severe renal impairment (creatinine clearance ARN-509 <30 mL/min) [25] or moderate liver disease (Child–Pugh–Turcotte class B) [26]. A pharmacokinetic study of 32 patients LGK-974 price switched from Atripla® (Bristol Myers Squibb, New York, NY, USA & Gilead Inc, Foster City, CA, USA) (fixed-dose combination of EFV and TDF/FTC) to Stribild showed reduced EVG concentrations during the first week as a result of glucuronosyl transferase induction by EFV. However, the median EFV Ctau remained above the IC90 of wild-type HIV for at least 4 weeks and, by the end of the first week,

the median EVG Ctau was threefold higher than the IC95, suggesting that EFV activity is maintained while EVG concentrations reach therapeutic concentrations [27]. A phase IIIb study is evaluating the safety of a regimen switch from Atripla to Stribild in terms of continued viral suppression. Cobicistat and Drug–Drug Interactions Due to its inhibition of CYP enzymes,

it is anticipated that COBI exposure will result in drug–drug interactions similar to those seen with RTV (see above). However, few studies have examined the effects of COBI on the plasma concentrations of other drugs and until the results of such studies emerge, it would appear prudent to avoid COBI in patients who require drugs with a narrow therapeutic index (e.g. cancer chemotherapy, digoxin) or drugs that are contraindicated or require major dose adjustment in those on RTV. Further and up-to-date information is available on the HIV Drug Adenosine Interactions webpage [28]. Cobicistat-Containing HIV Therapy: Results from the Phase III Clinical Trials Programme The results of three studies have been presented to date; two studies investigated the efficacy and safety of Stribild [29–32], while the third study compared COBI with RTV, each co-administered with ATV and TDF/FTC [33]. The GS-US-236-0102 and 0103 studies are ongoing phase III, double-blind, randomised, placebo-controlled trials of antiretroviral-naïve HIV-1-positive adults [31, 32]. Patients with a baseline HIV RNA measurement of >5,000 copies/mL were randomised 1:1 to Stribild or Atripla [0102 study], or to Stribild or TDF/FTC/ATV/RTV [0103 study].